Civilization Ventures (inquiries to info@civilizationventures.com) invests in visionary founders that are leading the future of health tech and biology-driven innovation. We aim to be the first check and lead investor in highly disruptive companies in synthetic biology and exponential health tech (genomics, diagnostics, digital health, AI, personalized and regenerative medicine). Our team comprises serial entrepreneurs and industry thought leaders who work tirelessly to help each of our portfolio companies succeed. We celebrated our first "unicorn" exit in 2018 with the public listing of gene therapy leader Rocket Pharma (NASDAQ: RCKT) and our second exit with the acquisition of Singular Bio (non-invasive prenatal testing) by Invitae.